New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDCOPD [updated 2018]. Available from: http://www.goldcopd.orgAccessed February 18, 2018
   Google Scholar
• World Health OrganizationChronic obstructive pulmonary disease (COPD) Updated2017 Available from: http://www.who.int/media-centre/factsheets/fs315/enAccessed February 18, 2018
   Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• LandisSHMuellerovaHManninoDMContinuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
   PubMed Web of Science ®Google Scholar
• RennardSDecramerMCalverleyPMImpact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International SurveyEur Respir J200220479980512412667
   PubMed Web of Science ®Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
   PubMed Web of Science ®Google Scholar
• MiravitllesMSorianoJBGarcía-RíoFPrevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activitiesThorax2009641086386819553233
   PubMed Web of Science ®Google Scholar
• NascimentoOACamelierARosaFWChronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO studyBraz J Med Biol Res200740788789517653440
   PubMed Web of Science ®Google Scholar
• ShahabLJarvisMJBrittonJWestRPrevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sampleThorax200661121043104717040932
   PubMed Web of Science ®Google Scholar
• BarnesNCalverleyPMKaplanARabeKFChronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD surveyBMC Pulm Med2013135423971625
   PubMed Web of Science ®Google Scholar
• MiravitllesMWorthHCataluñaJJObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespir Res20141512225331383
   PubMed Web of Science ®Google Scholar
• PriceDSmallMMilliganGHigginsVGilEGEstruchJImpact of night-time symptoms in COPD: a real-world study in five European countriesInt J Chron Obstruct Pulmon Dis2013859560324348032
   PubMed Web of Science ®Google Scholar
• UzaslanEMahboubBBejiMThe burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE studyRespir Med2012106Suppl 2S45S5923290704
   PubMed Web of Science ®Google Scholar
• JonesPWBrusselleGdal NegroRWPatient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in EuropePrim Care Respir J201221332933622885563
   PubMedGoogle Scholar
• TsiligianniIKocksJTzanakisNSiafakasNvan der MolenTFactors that influence disease-specific quality of life or health status in patients with COPD: a systematic review and meta-analysis of Pearson correlationsPrim Care Respir J201120325726821472192
   PubMedGoogle Scholar
• DingBSmallMHolmgrenUA cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classificationsInt J Chron Obstruct Pulmon Dis2017121527153728579771
   PubMed Web of Science ®Google Scholar
• AstraZenecaTudorza Pressair [prescribing information]2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202450s006lbl.pdfAccessed February 18, 2018
   Google Scholar
• AstraZenecaEklira Genuair [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdfAccessed December 11, 2017
   Google Scholar
• NovartisSeebri Neohaler [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207923s002lbl.pdfAccessed February 18, 2018
   Google Scholar
• Novartis EuropharmSeebri Breezhaler [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed December 11, 2017
   Google Scholar
• Boehringer Ingelheim International GmbHSpiriva Respimat [summary of product characteristics]2017 Available from: https://www.spiriva.com/global/sites/default/files/Spiriva%20Respimat%20SmPC%2013%20Jan%202017.pdfAccessed February 18, 2018
   Google Scholar
• Boehringer IngelheimSpiriva Respimat [prescribing information]2017 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdfAccessed February 18, 2018
   Google Scholar
• GlaxoSmithKlineIncruse Ellipta [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205382s008lbl.pdfAccessed February 18, 2018
   Google Scholar
• Glaxo GroupIncruse Ellipta [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002809/WC500167430.pdfAccessed December 11, 2017
   Google Scholar
• ScheringForadil Aerolizer [prescribing information]2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdfAccessed February 18, 2018
   Google Scholar
• Novartis PharmaceuticalsForadil [summary of product characteristics]2016 Available from: https://www.medicines.org.uk/emc/medicine/1286Accessed February 5, 2018
   Google Scholar
• Sunovion PharmaceuticalsArcapta Neohaler [prescribing information]2017 Available from: https://www.arcapta.com/Arcapta-Prescribing-Information.pdfAccessed January 19, 2018
   Google Scholar
• Novartis EuropharmOnbrez Breezhaler [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001114/WC500053732.pdfAccessed December 11, 2017
   Google Scholar
• Boehringer IngelheimStriverdi Respimat [summary of product characteristics]2016 Available from: https://www.medicines.org.uk/emc/medicine/28992Accessed February 18, 2018
   Google Scholar
• Boehringer IngelheimStriverdi Respimat [prescribing information]2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203108s003lbl.pdfAccessed February 18, 2018
   Google Scholar
• Glaxo WellcomeSerevent Accuhaler [summary of product characteristics]2014 Available from: https://www.medicines.org.uk/emc/medicine/91Accessed February 18, 2018
   Google Scholar
• LaubeBLJanssensHMde JonghFHWhat the pulmonary specialist should know about the new inhalation therapiesEur Respir J20113761308141721310878
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• D’UrzoAKardosPWisemanRPractical considerations when prescribing a long-acting muscarinic antagonist for patients with COPDInt J Chron Obstruct Pulmon Dis2018131089110429670345
   PubMed Web of Science ®Google Scholar
• IsmailaASHuismanEPunekarYKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2015102495251726604738
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD010844
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• IkedaTAnisuzzamanASYoshikiHRegional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airwaysBr J Pharmacol201216661804181422300233
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMJenkinsCRHurdSSGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summaryAm J Respir Crit Care Med200116351256127611316667
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPD updated2011 Available from: http://www.goldcopd.org
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPD updated2016 Available from: http://www.goldcopd.orgAccessed October 30, 2016
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPD updated2017 Available from: http://www.goldcopd.orgAccessed November 1, 2017
   Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol–glycopyrronium versus salmeterol–fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• CalverleyPMTetzlaffKVogelmeierCEosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201719691219122128306321
   PubMed Web of Science ®Google Scholar
• Pearl TherapeuticsStudy to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (ETHOS) Available from: https://clinicaltrials.gov/ct2/show/NCT2465567. NLM identifier: NCT2465567Accessed February 18, 2018
   Google Scholar
• PascoeSJLipsonDALocantoreNA phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocolEur Respir J201648232033027418551
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• FrithPAshmawiSKrishnamurthySAssessing direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in moderate to severe symptomatic COPD patients: the FLASH studyRespirology201722Suppl 3AOL011
   Google Scholar
• YuAPGuérinAPonce de LeonDTherapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ201114448649621679019
   PubMedGoogle Scholar
• AstraZenecaDuaklir Genuair [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003745/WC500178413.pdfAccessed December 11, 2017
   Google Scholar
• AstraZeneca PharmaceuticalsBevespi Aerosphere [prescribing information]2017 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed February 5, 2018
   Google Scholar
• Novartis EuropharmUltibro Breezhaler [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdfAccessed December 11, 2017
   Google Scholar
• Novartis PharmaceuticalsUtibron Neohaler [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207930s002lbl.pdfAccessed February 18, 2018
   Google Scholar
• Boehringer IngelheimSpiolto Respimat [summary of product characteristics]2017 Available from: https://www.medicines.org.uk/emc/medicine/30495Accessed February 18, 2018
   Google Scholar
• Glaxo GroupAnoro Ellipta [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdfAccessed December 11, 2017
   Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel co-suspension delivery technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 µg therapy in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• MartinezFJFabbriLMFergusonGTBaseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPDChest201715261169117828720336
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPOraJPuxedduECazzolaMMateraMGLABA/LAMA combination in COPD: a meta-analysis on the duration of treatmentEur Respir Rev20172614316004328096283
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• FeldmanGJSousaARLipsonDAComparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized studyAdv Ther201734112518253329094315
   PubMed Web of Science ®Google Scholar
• KerwinEFergusonGTSanjarSDual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studiesLung2017195673974728993871
   PubMed Web of Science ®Google Scholar
• AstraZenecaEfficacy and safety of glycopyrronium/formoterol fumarate fixed-dose combination relative to umeclidinium/vilanterol fixed-dose combination over 24 weeks in patients with moderate to very severe chronic obstructive pulmonary disease (AERISTO) Available from: https://clinicaltrials.gov/ct2/show/NCT3162055. NLM identifier: NCT3162055Accessed January 16, 2018
   Google Scholar
• BoniniMUsmaniOSThe importance of inhaler devices in the treatment of COPDCOPD Res Pract201519
   Google Scholar
• BraidoFChrystynHBaiardiniI“Trying, but failing”: the role of inhaler technique and mode of delivery in respiratory medication adherenceJ Allergy Clin Immunol201645823832
   Web of Science ®Google Scholar
• RabeKFGFF MDI for the improvement of lung function in COPD: a look at the PINNACLE-1 and PINNACLE-2 data and beyondExpert Rev Clin Pharmacol201710768569828443352
   PubMed Web of Science ®Google Scholar
• MahlerDAWatermanLAGiffordAHPrevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus dry powder inhalerJ Aerosol Med Pulm Drug Deliv201326317417923025451
   PubMed Web of Science ®Google Scholar
• PrimeDde BackerWHamiltonMEffect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the Ellipta dry powder inhalerJ Aerosol Med Pulm Drug Deliv201528648649726372467
   PubMed Web of Science ®Google Scholar
• FergusonGTHickeyAJDwivediSCo-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseasesRespir Med2018134162329413503
   PubMed Web of Science ®Google Scholar
• VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
   PubMed Web of Science ®Google Scholar
• JoshiVLechuga-BallesterosDFlynnBDevelopment of mono, dual, and triple combination pMDIs without co-formulation effectResp Drug Deliv Eur20112383386
   Google Scholar
• Lechuga-BallesterosDNogaBVehringRCummingsRHDwivediSKNovel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem20113131703171821942257
   PubMed Web of Science ®Google Scholar
• DotyASchroederJVangKDrug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliabilityAAPS PharmSciTech201819283784429019170
   PubMed Web of Science ®Google Scholar
• FabbriLMKerwinEMSpangenthalSDose-response to inhaled glycopyrrolate delivered with a novel co-suspension delivery technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDRespir Res20161710927586537
   PubMed Web of Science ®Google Scholar
• QuinnDSealeJPReisnerCA randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPDRespir Med201410891327133525060541
   PubMed Web of Science ®Google Scholar
• ReisnerCOrevilloCFernandezCPooled analyses of five phase 2B studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 µg for phase III developmentEur Respir J201342Suppl 57P4153
   Google Scholar
• ReisnerCFernandezCRoseEStCharacterization of the dose response of Pearl Therapeutics’ LAMA MDI (GP MDI, PT001) from 36 micrograms to 600 nanograms BID: results from an integrated analysis of phase IIB studies in patients with COPDAm J Respir Crit Care Med2013187A4274
   Web of Science ®Google Scholar
• RennardSFogartyCReisnerCRandomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary diseaseBMC Pulm Med20141411825027304
   PubMed Web of Science ®Google Scholar
• SethiSFogartyCHananiaNAEfficacy of formoterol fumarate delivered by metered dose inhaler using co-suspension delivery technology versus Foradil Aerolizer in moderate-to-severe COPD: a randomized, dose-ranging studyChronic Obstr Pulm Dis2017412133
   Google Scholar
• RoseEStStromSFischerTPharmacokinetic (PK) bioequivalence and comparable efficacy/safety were demonstrated with Pearl Therapeutics’ formoterol fumarate MDI (FF MDI, PT005) compared to Foradil Aerolizer in a randomized, double-blind, placebo-controlled phase 2B study in patients with moderate to very severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012185A2927
   Google Scholar
• TashkinDPMartinezFJRodriguez-RoisinRA multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPDRespir Med2016120162427817811
   PubMed Web of Science ®Google Scholar
• ReisnerCFabbriLMKerwinEMA randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel co-suspension delivery technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseRespir Res2017181828061907
   PubMed Web of Science ®Google Scholar
• Pearl TherapeuticsStudy to evaluate single inhaled doses of PT001, PT003, PT005 and PT001 plus PT005 in healthy subjects Available from: https://clinicaltrials.gov/ct2/show/NCT0893971. NLM identifier: NCT0893971Accessed January 5, 2018
   Google Scholar
• BaraldoSTuratoGSaettaMPathophysiology of the small airways in chronic obstructive pulmonary diseaseRespiration2012842899722868355
   PubMed Web of Science ®Google Scholar
• UsmaniOSBarnesPJAssessing and treating small airways disease in asthma and chronic obstructive pulmonary diseaseAnn Med201244214615621679101
   PubMed Web of Science ®Google Scholar
• BiddiscombeMFMeahSNUnderwoodSRUsmaniOSComparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol depositionJ Aerosol Med Pulm Drug Deliv201124316517321453048
   PubMed Web of Science ®Google Scholar
• ChrystynHMethods to determine lung distribution of inhaled drugs: could gamma scintigraphy be the gold standard?Br J Clin Pharmacol200049652552810848715
   PubMed Web of Science ®Google Scholar
• DarquenneCFlemingJSKatzIBridging the gap between science and clinical efficacy: physiology, imaging, and modeling of aerosols in the lungJ Aerosol Med Pulm Drug Deliv201629210712626829187
   PubMed Web of Science ®Google Scholar
• NewmanSBennettWDBiddiscombeMStandardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled productsJ Aerosol Med Pulm Drug Deliv201225Suppl 1S10S2823215844
   PubMed Web of Science ®Google Scholar
• TaylorGWarrenSDwivediSGamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technologyEur J Pharm Sci201811145045729055732
   PubMed Web of Science ®Google Scholar
• de BackerWDevolderAPoliGLung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patientsJ Aerosol Med Pulm Drug Deliv201023313714820109122
   PubMed Web of Science ®Google Scholar
• O’DonnellDEImpacting patient-centred outcomes in COPD: breathlessness and exercise toleranceEur Respir Rev200615993741
   Google Scholar
• FergusonGTWhy does the lung hyperinflate?Proc Am Thorac Soc20063217617916565428
   PubMedGoogle Scholar
• ThomasMDecramerMO’DonnellDENo room to breathe: the importance of lung hyperinflation in COPDPrim Care Respir J201322110111123429861
   PubMedGoogle Scholar
• DiazOVillafrancaCGhezzoHRole of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at restEur Respir J200016226927510968502
   PubMed Web of Science ®Google Scholar
• CasanovaCCoteCde TorresJPInspiratory-to-Total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171659159715591470
   PubMed Web of Science ®Google Scholar
• CelliBRPredictors of mortality in COPDRespir Med2010104677377920417082
   PubMed Web of Science ®Google Scholar
• BeehKMBurgelPRFranssenFMHow do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?Am J Respir Crit Care Med2017196213914927922741
   PubMed Web of Science ®Google Scholar
• ReisnerCGottschlichGFakihF24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPDRespir Res201718115728821260
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRFrithPEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPDEur Respir J2017494160134828424359
   PubMed Web of Science ®Google Scholar
• SinghSMaltaisFTombsLChurchAIqbalARileyJHEffect of umeclidinium/vilanterol (UMEC/VI) on inspiratory capacity/total lung capacity ratio in hyperinflated COPD patientsPoster PA1493 presented at: European Respiratory Society International CongressSeptember 26–30, 2015Amsterdam
   Google Scholar
• CalzettaLOraJCavalliFRoglianiPO’DonnellDECazzolaMImpact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysisRespir Med201712918919828732830
   PubMed Web of Science ®Google Scholar
• de BackerJWVosWGDevolderAComputational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilationJ Biomech200841110611317698073
   PubMed Web of Science ®Google Scholar
• de BackerLAVosWde BackerJvan HolsbekeCVinchurkarSde BackerWThe acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function studyEur Respir J201240229830522183484
   PubMed Web of Science ®Google Scholar
• de BackerWde BackerJVosWFunctional respiratory imaging (FRI) and lung function assessment of glycopyrronium/formoterol fumarate dihydrate fixed-dose combination delivered using novel co-suspension delivery technology (GFF MDI) in COPDEur Respir J201750Suppl 61OA4404
   Google Scholar
• Pearl TherapeuticsA study to assess the effects of PT001 and PT005 MDI on specific image based parameters in subjects with moderate to severe COPD Available from: https://clinicaltrials.gov/ct2/show/NCT2937584. NLM identifier: NCT2937584Accessed February 23, 2018
   Google Scholar
• MartinezFJRabeKFRodriguez-RoisinRBeneficial effect of the novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination delivered by MDI in GOLD A and B COPD patients: pooled analyses from PINNACLE-1 and -2Am J Respir Crit Care Med2016193A6785
   Web of Science ®Google Scholar
• FabbriLMMartinezFRabeKFBeneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patientsEur Respir J201648Suppl 60PA310
   Google Scholar
• MartinezFJFabbriLMFergusonGTEffect of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) delivered by novel co-suspension delivery technology on daily symptoms in patients with COPDAm J Respir Crit Care Med2017195A5469
   Web of Science ®Google Scholar
• AnzuetoAVogelmeierCKostikasKThe effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPDInt J Chron Obstruct Pulmon Dis2017121325133728496316
   PubMed Web of Science ®Google Scholar
• RabeKFMartinezFJRodriguez-RoisinRLAMA/LABA glycopyrrolate/formoterol fixed-dose combination, delivered using a novel MDI co-suspension delivery technology reduces risk of clinically important deteriorations in COPD versus placebo and monocomponent MDIsAm J Respir Crit Care Med2017195A3594
   Web of Science ®Google Scholar
• SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2016111413142427445468
   PubMed Web of Science ®Google Scholar
• SinghDD’UrzoADChuecosFMuñozAGarcia GilEReduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterolRespir Res201718110628558833
   PubMed Web of Science ®Google Scholar
• BuhlRMcgarveyLKornSBenefits of tiotropium + olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD BAm J Respir Crit Care Med2016193A6779
   Web of Science ®Google Scholar
• ZhouYZhongNSLiXTiotropium in early-stage chronic obstructive pulmonary diseaseN Engl J Med20173771092393528877027
   PubMed Web of Science ®Google Scholar
• ReganEALynchDACurran-EverettDClinical and radiologic disease in smokers with normal spirometryJAMA Intern Med201517591539154926098755
   PubMed Web of Science ®Google Scholar
• WoodruffPGBarrRGBleeckerEClinical significance of symptoms in smokers with preserved pulmonary functionN Engl J Med2016374191811182127168432
   PubMed Web of Science ®Google Scholar
• JonesRØstremAOptimising pharmacological maintenance treatment for COPD in primary carePrim Care Respir J2011201334521103801
   PubMedGoogle Scholar
• AmbrosinoNFoglioKBalzanoGTiotropium and exercise training in COPD patients: effects on dyspnea and exercise toleranceInt J Chron Obstruct Pulmon Dis20083477178019281092
   PubMedGoogle Scholar
• CasaburiRKukafkaDCooperCBWitekTJKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest2005127380981715764761
   PubMed Web of Science ®Google Scholar
• HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPIn stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroidsEvid Based Med201722518318428801320
   PubMedGoogle Scholar